Prescription Drugs Market Research Reports & Industry Analysis
The prescription drugs industry is a key cornerstone of healthcare, delivering vital medications that improve and save lives. As this industry continues to evolve, understanding its nuances can be an ongoing challenge. MarketResearch.com provides hundreds of authoritative prescription drugs market research reports to help stakeholders understand the shifting market landscape and devise effective business strategies.
The Latest Prescription Drugs Market Analysis
- We provide data-packed reports on a wide range of product types, therapeutic areas, regions, and companies.
- Our research includes in-depth analyses of prescription drug market size, growth forecasts, and drivers and challenges.
- In addition, we cover the rise of personalized medicine and gene therapies, as well as regulatory issues and pricing models.
Your Dedicated Research Partner
As the prescription drugs industry shifts and changes, MarketResearch.com equips you with the tools to thrive. Trusted for decades as a reliable research partner, our clients include top pharmaceutical companies, investment banks, and universities. Whether you are exploring new markets or seeking to futureproof your business, our prescription drugs industry research reports offer a wealth of knowledge to inform your strategy. Get started by exploring our vast selection of reports on the prescription drugs industry today.
Prescription Drugs Industry Research & Market Reports
-
Iron Deficiency Anemia Therapy
... 2030, growing at a CAGR of 7.6% over the analysis period 2024-2030. Oral Iron Therapy, one of the segments analyzed in the report, is expected to record a 6.9% CAGR and reach US$11.1 Billion by ... Read More
-
TNF Inhibitors
... CAGR of 6.4% over the analysis period 2024-2030. Rheumatoid Arthritis Application, one of the segments analyzed in the report, is expected to record a 8.3% CAGR and reach US$22.7 Billion by the end of the ... Read More
-
Focal Segmental Glomerulosclerosis
... at a CAGR of 6.6% over the analysis period 2024-2030. Primary Disease, one of the segments analyzed in the report, is expected to record a 6.6% CAGR and reach US$17.9 Billion by the end of ... Read More
-
Vasculitis Treatment
... CAGR of 4.4% over the analysis period 2024-2030. Immunosuppressants, one of the segments analyzed in the report, is expected to record a 3.8% CAGR and reach US$153.8 Million by the end of the analysis period. ... Read More
-
Coating Agents
... CAGR of 7.0% over the analysis period 2024-2030. The U.S. Market is Estimated at US$333.0 Million While China is Forecast to Grow at 10.5% CAGR The Coating Agents market in the U.S. is estimated at ... Read More
-
Cardiovascular Drugs
... CAGR of 3.4% over the analysis period 2024-2030. Anticoagulants, one of the segments analyzed in the report, is expected to record a 3.9% CAGR and reach US$57.7 Billion by the end of the analysis period. ... Read More
-
Antibiotics
... 3.1% over the analysis period 2024-2030. Penicillin, one of the segments analyzed in the report, is expected to record a 3.3% CAGR and reach US$15.7 Billion by the end of the analysis period. Growth in ... Read More
-
Multiple Myeloma Therapeutics
... at a CAGR of 14.5% over the analysis period 2024-2030. Chemotherapy & Other Drugs, one of the segments analyzed in the report, is expected to record a 15.3% CAGR and reach US$37.6 Billion by the ... Read More
-
Postpartum Hemorrhage (PPH) Treatment Devices
... Billion by 2030, growing at a CAGR of 4.6% over the analysis period 2024-2030. Uterine Balloon Tamponade, one of the segments analyzed in the report, is expected to record a 4.3% CAGR and reach US$521.7 ... Read More
-
Doxorubicin
... 5.8% over the analysis period 2024-2030. Breast Cancer Application, one of the segments analyzed in the report, is expected to record a 5.6% CAGR and reach US$374.1 Million by the end of the analysis period. ... Read More
-
Isosorbide - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030
... forecast period 2024-2030. North American market for Isosorbide was valued at $ 30.30 million in 2023 and will reach $ 68.92 million by 2030, at a CAGR of 13.55% during the forecast period of 2024 ... Read More
-
Pharmacokinetics Services
... CAGR of 6.4% over the analysis period 2024-2030. Small Molecules, one of the segments analyzed in the report, is expected to record a 6.0% CAGR and reach US$1.2 Billion by the end of the analysis ... Read More
-
Fondaparinux
... 5.4% over the analysis period 2024-2030. Generic Fondaparinux, one of the segments analyzed in the report, is expected to record a 6.1% CAGR and reach US$643.5 Million by the end of the analysis period. Growth ... Read More
-
Immunomodulators
... 5.7% over the analysis period 2024-2030. Immunosuppressants, one of the segments analyzed in the report, is expected to record a 6.1% CAGR and reach US$209.8 Million by the end of the analysis period. Growth in ... Read More
-
Bipolar Disorder Therapeutics
... at a CAGR of 3.4% over the analysis period 2024-2030. Antipsychotic Drugs, one of the segments analyzed in the report, is expected to record a 3.3% CAGR and reach US$3.5 Billion by the end of ... Read More
-
Human Growth Hormone Drugs
... 2030, growing at a CAGR of 4.2% over the analysis period 2024-2030. Subcutaneous Administration, one of the segments analyzed in the report, is expected to record a 4.7% CAGR and reach US$3.4 Billion by the ... Read More
-
Active Pharmaceutical Ingredients (API)
... 2030, growing at a CAGR of 6.3% over the analysis period 2024-2030. Innovative APIs, one of the segments analyzed in the report, is expected to record a 6.0% CAGR and reach US$240.8 Billion by the ... Read More
-
Cancer Supportive Care
... at a CAGR of 2.2% over the analysis period 2024-2030. Opioids, one of the segments analyzed in the report, is expected to record a 2.3% CAGR and reach US$11.1 Billion by the end of the ... Read More
-
Rabies Treatment
... CAGR of 4.2% over the analysis period 2024-2030. Rabies Vaccines, one of the segments analyzed in the report, is expected to record a 4.6% CAGR and reach US$4.6 Billion by the end of the analysis ... Read More
-
Premature Ejaculation Treatment
... at a CAGR of 7.4% over the analysis period 2024-2030. Selective Serotonin Reuptake Inhibitors (SSRIs), one of the segments analyzed in the report, is expected to record a 6.9% CAGR and reach US$1.8 Billion by ... Read More
-
Sickle Cell Disease Treatment
... 2030, growing at a CAGR of 18.7% over the analysis period 2024-2030. Blood Transfusion, one of the segments analyzed in the report, is expected to record a 19.3% CAGR and reach US$6.5 Billion by the ... Read More
-
Krabbe Disease Treatment
... at a CAGR of 6.2% over the analysis period 2024-2030. Anticonvulsants, one of the segments analyzed in the report, is expected to record a 5.3% CAGR and reach US$823.5 Million by the end of the ... Read More
-
Diabetic Macular Edema Treatment
... 2030, growing at a CAGR of 2.2% over the analysis period 2024-2030. Anti-VEGF, one of the segments analyzed in the report, is expected to record a 2.5% CAGR and reach US$2.7 Billion by the end ... Read More
-
MRSA Drugs
... CAGR of 4.5% over the analysis period 2024-2030. Glycopeptides & Lipoglycopeptides, one of the segments analyzed in the report, is expected to record a 4.5% CAGR and reach US$726.5 Million by the end of the ... Read More
-
Iron Drugs
... CAGR of 7.9% over the analysis period 2024-2030. Oral Drugs, one of the segments analyzed in the report, is expected to record a 9.2% CAGR and reach US$6.7 Billion by the end of the analysis ... Read More
Research Assistance
